Safety & side effects
In the short, controlled studies that exist, most treatment-emergent events were mild to moderate and were generally at…
What we know about safety, and the large gaps
In the short, controlled studies that exist, most treatment-emergent events were mild to moderate and were generally attributed to the surgery or the underlying disease rather than to ipamorelin. That is reassuring as far as it goes, and it does not go far: every published human exposure was single-dose or lasted at most about a week, and the one efficacy trial still recorded serious events, including two deaths, in the ipamorelin arm.
This unit separates the reassuring short-term data from the real, mostly theoretical, longer-term concerns: blood sugar, IGF-1 and cancer-risk questions, the acromegaly-spectrum risks of chronic stimulation, who should avoid it, and what monitoring a cautious clinician would want. As always, this is education, not medical advice.